DXB · ASX

Dimerix Limited (ASX:DXB)

AU$0.32

 -0.005 (-1.562%)
ASX:Live
20/12/2024 04:10:10 PM
HALO Small HALO Ords HALO Consensus Value GROWTH AUS EMA 125 Breakdown +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

DXB Overview

DXB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Neutral

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About DXB

Website

Dimerix Limited

Telephone

61.8.1300.8133

Address

Fitzroy 425 Smith Street Melbourne, Victoria (VIC) 3065

Description

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. It focuses on the development of Dimerix DMX-200 drug candidate in both renal and respiratory indications and the development of Dimerix DMX-700 pre-clinical asset in Chronic Obstructive Pulmonary Disease. The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.

DXB Price Chart

Key Stats

Market Cap

AU$189.67M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.16 - 0.67

Trade Value (12mth)

AU$335,738.00

1 week

-8.57%

1 month

-4.48%

YTD

28%

1 year

88.24%

All time high

44.74

Key Fundamentals

EPS 3 yr Growth

19.30%

EBITDA Margin

%

Operating Cashflow

-$7m

Free Cash Flow Return

-59.90%

ROIC

-141.00%

Interest Coverage

N/A

Quick Ratio

9.50

Other Data

Shares on Issue (Fully Dilluted)

489m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.14

DXB Announcements

Latest Announcements

Date Announcements

16 December 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

20 November 24

Successful planned IDMC review of ACTION3 trial

×

Successful planned IDMC review of ACTION3 trial

18 November 24

Investor Presentation

×

Investor Presentation

15 November 24

Dimerix Receives $7.9M R&D Tax Incentive Rebate

×

Dimerix Receives $7.9M R&D Tax Incentive Rebate

08 November 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

07 November 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

06 November 24

Dimerix to Host Technical Webinar on PARASOL FSGS Insights

×

Dimerix to Host Technical Webinar on PARASOL FSGS Insights

01 November 24

NEPTUNE Study Network to Enhance Phase 3 Recruitment in US

×

NEPTUNE Study Network to Enhance Phase 3 Recruitment in US

31 October 24

Quarterly Appendix 4C and Activities Report

×

Quarterly Appendix 4C and Activities Report

28 October 24

Project PARASOL Update & Medical Advisory Board Appointment

×

Project PARASOL Update & Medical Advisory Board Appointment

25 October 24

Change of Director's Interest Notice - CS,HA,NW,SP & MD

×

Change of Director's Interest Notice - CS,HA,NW,SP & MD

22 October 24

Notification regarding unquoted securities - DXB

×

Notification regarding unquoted securities - DXB

15 October 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

01 October 24

Chair Address and AGM Presentation

×

Chair Address and AGM Presentation

01 October 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

01 October 24

Results of Meeting

×

Results of Meeting

17 September 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

16 September 24

ACTION3 Trial Recruitment and Multiregion Trial Site Update

×

ACTION3 Trial Recruitment and Multiregion Trial Site Update

13 September 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

12 September 24

First Paediatric Site Activated and Trial Update

×

First Paediatric Site Activated and Trial Update

11 September 24

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

10 September 24

First patient enters into Open Label Extension study

×

First patient enters into Open Label Extension study

02 September 24

Letter to Shareholders, Notice of AGM & Proxy Form

×

Letter to Shareholders, Notice of AGM & Proxy Form

29 August 24

Preliminary Final Report

×

Preliminary Final Report

29 August 24

Annual Report

×

Annual Report

DXB Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.8 -21.1 11.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.04 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.6 -12.4 19.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -38.1 -63.1 -3.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.04 0.02 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.04 0.02 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 506.0 -65.2 115.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 300 326 453 Lock Lock Lock
Basic m Lock Lock Lock Lock 300 326 453 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 17 23 26 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.3 -10.8 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -17 -23 -25 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.3 -34.7 -10.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -6,181.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -17 -23 -25 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.2 -34.6 -10.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -6,193.4 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -17 -23 -25 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -6 -9 -8 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -10 -14 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.6 -31.6 -23.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -4,190.6 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -13 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 18 11 21 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -13 -13 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -107.8 5.3 42.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -17.8 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 10 8 22 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 16 18 32 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -10 -2 -22 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 12 14 Lock Lock Lock
Equity $m Lock Lock Lock Lock 14 6 18 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 14 6 18 Lock Lock Lock
     Growth % Lock Lock Lock Lock 883.6 -58.7 206.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -63.6 -77.7 -53.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -72.7 -231.5 -93.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -161.4 -172.8 -166.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -131.9 -135.3 -141.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -168.9 -124.8 -59.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -14,573.0 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.6 0.1 0.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -66.3 -34.1 -120.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.1 1.5 9.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.1 1.5 9.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 58.4 45.0 69.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -664.0 -108.3 -215.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 74.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 -6,137.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 -78.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -63.6 -77.7 -53.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 3.0 1.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -72.7 -231.5 -93.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -72.7 -231.5 -93.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 8,541.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 8,541.5 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 13,129.5 20,391.1 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -13,129.5 -20,391.1 8,541.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.14%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

DXB Shortsell

Frequently Asked Questions

The current share price of Dimerix Limited (DXB:ASX) is AU$0.32.
The 52-week high share price for Dimerix Limited (DXB:ASX) is AU$0.67.
The 52-week low share price for Dimerix Limited (DXB:ASX)? is AU$0.16.
Dimerix Limited (DXB:ASX) does not pay a dividend.
Dimerix Limited (DXB:ASX) does not pay a dividend.
Dimerix Limited (DXB:ASX) does not offer franking credits.
Dimerix Limited (DXB:ASX) is classified in the Healthcare.
The current P/E ratio for Dimerix Limited (DXB:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.